biostudies-literature002900Ip MSNEI NIH HHS1101-14https://www.ebi.ac.uk/biostudies/studies/S-EPMC2872173biostudies-literatureUnknown127(9)<h4>Objective</h4>To compare the efficacy and safety of 1-mg and 4-mg doses of preservative-free intravitreal triamcinolone with observation for eyes with vision loss associated with macular edema secondary to perfused central retinal vein occlusion (CRVO).<h4>Methods</h4>Multicenter, randomized, clinical trial of 271 participants.<h4>Main outcome measure</h4>Gain in visual acuity letter score of 15 or more from baseline to month 12.<h4>Results</h4>Seven percent, 27%, and 26% of participants achieved the primary outcome in the observation, 1-mg, and 4-mg groups, respectively. The odds of achieving the primary outcome were 5.0 times greater in the 1-mg group than the observation group (odds ratio [OR], 5.0; 95% confidence interval [CI], 1.8-14.1; P = .001) and 5.0 times greater in 4-mg group than the observation group (OR, 5.0; 95% CI, 1.8-14.4; P = .001); there was no difference identified between the 1-mg and 4-mg groups (OR, 1.0; 95% CI, 0.5-2.1; P = .97). The rates of elevated intraocular pressure and cataract were similar for the observation and 1-mg groups, but higher in the 4-mg group.<h4>Conclusions</h4>Intravitreal triamcinolone is superior to observation for treating vision loss associated with macular edema secondary to CRVO in patients who have characteristics similar to those in the SCORE-CRVO trial. The 1-mg dose has a safety profile superior to that of the 4-mg dose. Application to Clinical Practice Intravitreal triamcinolone in a 1-mg dose, following the retreatment criteria applied in the SCORE Study, should be considered for up to 1 year, and possibly 2 years, for patients with characteristics similar to those in the SCORE-CRVO trial. Trial Registration clinicaltrials.gov Identifier: NCT00105027.Archives of ophthalmology (Chicago, Ill. : 1960)A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.PMC2872173U10 EY014404-03U10 EY014404U10 EY014404-02U10 EY014404-01U10 EY014404-04S15U10EY014351U10 EY014404-02S1U10 EY014404-04U10 EY014351-02U10 EY014352-04U10 EY014351-01U10 EY014352-01U10 EY014351-05U10 EY014351-04U10 EY014352-02U10 EY014352-03U10 EY014351-03U10 EY014352-04S15U10EY014404U10 EY014351U10 EY014351-05S1U10 EY0143525U10EY014352U10 EY023529West KFrawley MWest MDiaz-Rohena RThornton TCapone APahk PSchulz LBrugnoni NTalbert MDavila LDBrucker AMagee MBerger ACummings PBerger BGridine MBerger JEnloe JKendall BIbisevic MGaultney JBailey TBalea GJohnson MWCapone LFore CBailey MMcLaughlin SFletcher DBusch SRock SFraser-Neumann YHarper MBartlett TBhatia SParikh NRandhawa SQuiram PHoward TGoates DGillespie PMarx JBaumal CSantiago GMcNames RZachariah RWillman LOldag VWealti AMoos MOkun NTai KChung MMittra RKeeling MReilly SDrescher TPoulose AJudd SCassa GCuellar DLansing MRichmond PHelms JLadd BOlson MMcNamara EFishburne BSherley CHenson MKnips EOdil RVoltz KHenson HBoyd LKrzykowski QSharma APearson PADuker JBackes DAgarwal ARago JGuist MLincoln PBoyd KBurke JMobley SMcOwen MChen SShankle JBurke KCantrill HMcManus RSkelly MRekow SStoutenburg AChen MSomers GTyler MBalasubramaniam UTyler LDeininger DNiemi SNelson KAbe KSharma MKlesert TChen EChristopherson KHoffmeyer GMartinez MWeckter RGarretson BDunn BOlson JGorin MJohnson JLaPrise TJohnson MCrowley GTutko JCleverly SSullivan KJohnson RJordan DSpalding SKurtz JHutchison CRidley MMurphy JSimjanoski EBivins FJohnson BJohnson CDuPont JHartnett MESams WHanamoto FMartin DWalski JMarks JAnderson JGamblain JParke JCorona RBelt JBasefsky JAnderson EAnderson FGraf JRath PShah GWilmarth MNanda MRath SShah KFecko TCooke LWeinberg DDiLoreto DMasini RBrockman NBeringer JManochio MJasso LMahmood YMilam WScott IUSun XKRezaei KScrivner EFlowers ANovalis CKeller KMaldonado JPeterson DWalter LKeller CScolaro MPeterson JIndermill CFedick NStallman JPeterson TWalters CAltaweel MDesai KMiskell BFournier LGammage MHarvey PThomas DMincey GKarnolt ACole MCiardella AMunn GEThomas MGeraghty SBridges CCousins GHetherington HLambert HMBlumenkranz MSSlusher MMLeff SGrout STewari AQuinlan EHendrickson JYou TMarino KMinturn JGreer LSchillace LMerry LLayzer JSimmons-Denton JCroswell MHan DMofield GPohlman AZiolo FMarcus LYates PBaker CScalzo APimentel MRaeber MHaller JRial JMarcus DBaker ALeong CEmbrey MTilton EBatlle IBatlle KDunlap HBreehl BMercurio NDe La Garza RDilts VSteele TMariano JEverhart COgilvy STarter CIrizarry VFreeman BWehmeier JRoussel DRivellese MFulbright SPurvis HHendricks SBlaha GMullen LRamsay RRosenthal WSingerman LJLutman BPackard KAlworth KDietzman KZakov ZNBolet AOvase RFarrell HMendenhall CRam KCFarnsworth KJJehan FGartner MGore NGerson JMorehead KSolalinde KZapada GCouvillion SHarrison KLeBow AGrinnell CHanda JLyon AAguilos MPickell SRollins KBarnhart CCzajak TSnell BVan Dyke JYarian DSalib DShah CKulasa JPierce RGonzalez VLin RLin SLin THoerner SNelson-Parker EGonzalez NGomez CPierce KWright TPoston JSanborn GStrong JTaylor MHaller JAUribe PCantu MJames RKatz AGrimes CAddams LWirostko WCurtin DAbrams GShaikh OOwings SEbert EMirza RShaikh STroszak TLedbetter FChin MFigueroa MJHariprasad SGlatzer RDoherty ROzuna SGonzalez FAntoszyk AKrug SBressler NMPhiliph DPoland SShah SMSipperley JHolm LLatham SStarr JCain TCain MMcDonald HRLehrack LBay ESears JIra STerry JHasan SFan JDuCoty CGeorge RAldana IHolleschau AFredrickson DCain DTaylor-Ward MRoy MSayers ABaird AConnett JCMorley MAlvir AVallet NOsguthorpe RGreen JGreenberg PDiekmann ACheshier HGray KAi EKlancnik JJaffe GGreen SBleau LCasillo FNork TMOsuna SGhuman ATRutledge BCharlton AKlima KSuthar MPeters CWeeney LDrossner SGreven CJones BEAgresta EHurlbut-Miller PKrzystolik MBenson JAbdelghani WJumper JMButler-Grant EHill CHay PLonergan KMcIver FHay SAgustin EQuillen DKosinski BCantrell DLundquist AFarlow BAgustin RSolley WCooney MQuesada CMaranan LDawson PArcara CRobbins ESalinas CGerman EJones JArrington BNoorily SDuLong CPogosky SJones TTrythall CJanigian RManhart GFranklin CCombs JGaray LChaudhry IWallace PLarson SDoft BScott IMorris RCraig SOlszowy RMuir DAlfaro DVArenas SLietz FVittitow AHursky JLeverett KFardin BMilanovic CEichenbaum DSCORE Study Research GroupHwang THuff KMoss PCowen MKuppermann BHutchins RBlackmer KBurns RLafferty DCombs WSteinberg DSadikovic ZFaber DAvery KKey JO'Donnell LAvery RThompson WMcDougal PCollins JSimpson APollack JClark LPuklin JCiscato BSelchert KClark MWeeks RStrom JO'Brien DWilson JRaja SSannazzaro BSmoral LReg MGrunhaus RConnor TTang XSRitchie MBanks JConsolo CSalfer-Firestone DHamlet PHoran CIp MSCasazza ESorenson JEsquejo RLZacharias LSchocket LDavies SConcannon MFischer WRozenbajgier ZLoose IButton JZand PJacobson MNapoli DVaughan MEmmert DNapoli JCorliss CTeshima-McCormick SDyshanowitz DBearelly SMathura JLove KShelton HShelton GChong SFriberg TWaxman EDuBois KGalata SLindblad ARoth DFollano GOrth DHagin KSpaide RLucas WTarasewicz DSee RRouvier GKapoor SHerrera JDoft BHFernandez CFernandez BFink BQuinchia EKeyser BJones CMWilson DAndreani GGallimore GGoings LGen SRigoni GSaldana GKenes JCarey JDDepp CKruzel MBrown DCallen NLauer ABrooks DHerrera AGuerrero PZacks DMorales JGarg SKnutson GShirkey BTorrisi PGoldberg MSun JFriedman SBarwick VMartidis AFackler TKubecka DSaroj NCoffey TFay CGraham MKhawly JSelter RMcKinney AIezzi RFriedman ECallanan DConley NGriffith NStarnes CChavez MAdkins TGriffith DWalters-Treon SYang SBenz MRauser MOh KDoran SRodriguez MGrisafe EBankert JRodriguez EVargo PKunimoto DLowd DDoherty MCleary TBlodi BASingletary PDoherty Dde Aguiar Marques LWalther KGoole MWing GFlanders JNiskanen JPerry-Raymond JAdhikari SPrenner JElledge JSrivastava SVazquez AFrasketi MBrink TMilch CJohnstone LBrown JJoseph DBoleman BRobinson CBrown STravis ABenton-Murray JOstroska PHolekamp NChatari LChristoff RMetelitsina TNobel VGrijalva JSlakter JTuttle CHawkins HWalker JLaizure BGreanoff GHampton GRMieler WElkomos GWalker RMcClain NMyers DJCornelius JNovak MCreighton JSanders JFisher MLovit HMcClain DRecchia FTing TDMcLeod KPusser PSingerman LMunana ANovak CLevy MGraterole GQuesnelle ADeinzer JMiller JRhodes RGallardo JLopez RToomey MCastillo SMiller PMiller RHackel RLopez JWong CLopez MLopez GTurner JLinares SRoss JMiller DWong KBhagat NArredondo LCastillo DFekrat SRoss DWong TMiner JKlein RLanier GRegan VMcArthur MKonior YParks MDickerson EOlsen TChiu EEsquejo-Leon RSterling ATopping TOlsen KBequette CGallardo GEngelbrech NMoreno OHenry KSaxe SBenevento JGrawl JRoberts PPolanco-Weaver LCadena IHassan TZimmer NJelemensky PDavis LDiSano FWells JChan CKDavis HChakrabarty ACalgaro LOrtega AMcVerry WNeely DGarcia YHejkal TRod MKoch WNeely KSneath MGarcia NKarow AOden NLCottrill MCortez LGarcia KGarcia LBye ARedmond MSchura SFleming JMyers LGarcia DEnlow JKwasniewski LAndresen TStevens TLiu JKostamaa HCampochiaro PWiskirchen TMedina TZarbin MAlexandrescu BBlackburn PTreuter TCahill NTLofton TBarragan LBraverman JHarris MRosen JCasiano MRaden RRomero JElmore JGuan EZajechowski MMagana LOwlia MGleed JMisch DBrowning DRutled BRusinek BShami MGregory VBennett TMutz KBennett SRosen RN'Dure FHoyle-Harris CLaurens AWhitehead CDurham EDev SSquires LCooper SYedavally SRay SCarnegie EPieramici DPrusak RFox LHallett JRuby ASchindledecker SStewart ASwafford LBressler SHuynh TChieh JFyles KFlaxel CShields KReed SBClark WLMoreci CWentlandt TPlous ONitzsche TRyan CSchafer MLRyan DRyan EStern BCook SEssman TGuenther MTramel LMehr DRen YDick JSchaefer TSuner IWoodcome HCassell MPope SNorris JThibault MTurton EMcDonough RCsaky KSung JVaradian SBryant TGeer BMikota RBryant JChobanoff SFu ABanalewicz ERoberts LWood MRoberts GKnight DLazarte VKinder KHarkleroad KSchmidt AWarren SShekar SPalcynski MWatson JWatson ESingh HDowell KRevella LGallegos SGabriel RKeith TCaldwell TMaggiano JBreit EColborn SCastellarin AHurley VWarren KJFigliulo CNuthi AGehlbach PFalk RPierce SJKiernan CVanVeldhuisen PCDavidson CDiaz CSu YTBucci JKiernan WRedford MWheatley HMGwyn Nafe MAlexander KTolentino MTrevino MFish JStone LFish RKaiser PKSmith DSmith CSmith ASchwartz JEarl MIvey KMcHugh KFish GChristianson DJCoxville JTruman KSmith SSmith RMallinga SSchachat ANyberg WAramayo PGross JChen HZFitz EWilliams MEliott DWilliams LFinkelstein DDubois JSteinkamp PAberman NPateva IRossi JPerkins TSabates FWilliams DSjoblom KSloan MWilliams GHodgden KChesbrough DWilliams CFeiner LDavis MDJablon EPatel NGonzalez VHCunningham TMorse PADixon BPatel SWeisz JStrickler ATakahara SHawks TCunningham MMurajda-Jumba SMilleson MSamaniego DCorey ECloud JSerfass MShawver LNasir MSilvis EHall JElman MSaldivar JVerne AElner SVarnadore LDemming SCisco JNolte SRessel TBlinder KIe DKelly SMcAteer CHamilton RSteinmetz KGoulding ADriver RWeidman FDugdale JFattori ARaskauskas PRadzyner HCivantos JStorie MMcMahon DKelly MHambrock CMiller-Long EMistler TJager RLange CCohen MGlessner ARothen MTrueman DBrogdon AMahoney SScheufele TCorey ROber MStolarczuk MBradley PKunkelman KLee SYGama VChristianson ESabates NMcDonald DColey TMcDonald JNiffenegger JBowman FKrzeminski VGill MCavanagh JEvans REvans MOverton KRyman LParker SSclafani LGothrup JSotirakos PKimbrough AMoon SLewis HHowell CGottlieb JLewis LTardif AMalpica BJeffers SMidlock PHenriques SNeist RGoodart RZimmer-Galler IRolfer SKoh SLight PNardi BChun DOliveira ALucko NTownsend-Patrick SZalewski MPostel EStallings AHolody LMack BStillberger MMonk MBoyer KWilcox LErickson DRichter BGlander KEChandra SMoses KBell GDrucker FBarnes CDAlvarez DCampanaro LWalsh MHuggans SBell THuertas CAfola LZalamea JPakulski JBretz SRice PGrassi MVann VGuel DAMcGilvra SStrickland JLanders MTaylor AKPendergast SHughes MMartin JLummis JOestreich NMahmoud TToth CMartin TEdwards PMcRay MTanner VHanson MJaimes ABui HMurphy HBland KGallia BLipkowitz JCarlton SMatthews DChan CMcMillan RSolomon SStepien KTantum TBetanzos GHickman AKohlhepp MNorton TAhuja RLieb DGentile RPicchiottino RHabib AChase KDugel PLee JEllorin LDorweiler ERedenbo EKarlsson ETsong JKim JGarcia-Garza GZegarra HLee DCarofanello CVernon KFreund KBGardner TPauley COstrander BBarouch FWertz FVahrenwald DLarrison WPrice RHolland CAdams JLampert SKim RAdams LSarin NWiegand THagemann LPatterson PStout JTPrice AAllen SPrice ELambert LFreisberg LAhmad SKegley EHanel SMeredith THerring MGauthier AFowell SMagallon RSpawn KTeske BIp MIlc MDaniels SKaminski LGarza CButcher TKrolnik DLobes LSchultz DBorthwick AMScrivano TConey JMruthyunjaya PTrump BFalcone PFagan DCiulla TStoltz RSoderling BFulghum LSternberg PLu SMayleben LPark DTreutel JMcCall LO'Neal MKourous Rezaei HNagle ASpivey RMaturi RWilliamson ASheth VEdema-Sillo PPhoebus JSmith-Brewer SZapata JBlodi BWillis AZapata GSage KTrese MRogers ABuddemeier AMadreperla SReiter KVarner RSStaples LGoad JLazar MTejada REller ANguyen QMcCuen BNguyen JHrisomalos NReichel EJoshi DNguyen LMargalit ECampbell JKiesel CCampbell AJimenez NPalmer MCampbell CHamel MForofonova T290falseA randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.<h4>Objective</h4>To compare the efficacy and safety of 1-mg and 4-mg doses of preservative-free intravitreal triamcinolone with observation for eyes with vision loss associated with macular edema secondary to perfused central retinal vein occlusion (CRVO).<h4>Methods</h4>Multicenter, randomized, clinical trial of 271 participants.<h4>Main outcome measure</h4>Gain in visual acuity letter score of 15 or more from baseline to month 12.<h4>Results</h4>Seven percent, 27%, and 26% of participants achieved the primary outcome in the observation, 1-mg, and 4-mg groups, respectively. The odds of achieving the primary outcome were 5.0 times greater in the 1-mg group than the observation group (odds ratio [OR], 5.0; 95% confidence interval [CI], 1.8-14.1; P = .001) and 5.0 times greater in 4-mg group than the observation group (OR, 5.0; 95% CI, 1.8-14.4; P = .001); there was no difference identified between the 1-mg and 4-mg groups (OR, 1.0; 95% CI, 0.5-2.1; P = .97). The rates of elevated intraocular pressure and cataract were similar for the observation and 1-mg groups, but higher in the 4-mg group.<h4>Conclusions</h4>Intravitreal triamcinolone is superior to observation for treating vision loss associated with macular edema secondary to CRVO in patients who have characteristics similar to those in the SCORE-CRVO trial. The 1-mg dose has a safety profile superior to that of the 4-mg dose. Application to Clinical Practice Intravitreal triamcinolone in a 1-mg dose, following the retreatment criteria applied in the SCORE Study, should be considered for up to 1 year, and possibly 2 years, for patients with characteristics similar to those in the SCORE-CRVO trial. Trial Registration clinicaltrials.gov Identifier: NCT00105027.2009-01-01T00:00:00Z2009 Sep2024-11-13T19:54:03.478Z2019-03-27T00:30:52ZS-EPMC28721731975241910.1001/archophthalmol.2009.234